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Abstracts / Osteoarthritis and Cartilage 20 (2012) S1–S9 S3capable of sensitizing peripheral nociceptors, has been demonstrated in
phase 3 clinical trials to result in signiﬁcant pain relief in OA, with the
magnitude of the pain relief being greater than what is observed with
NSAIDs in the same studies. Importantly, this approach has also been
shown to be effective in low back pain and is being investigated in
neuropathic pain models. Currently, the further development of this
class of drugs is on hold pending a more complete understanding of
their safety proﬁle. Centrally acting compounds, speciﬁcally serotonin-
norepinephrine reuptake inhibitors (SNRIs) have also been shown to
provide pain modiﬁcation in musculoskeletal pain conditions (OA, low
back pain), adding to the armamentarium available for the manage-
ment of these conditions. Novel topical agents as well as different
formulations of existing opioids are also being investigated at this time.
In terms of disease modiﬁcation, recent trials have examined the effects
of oral calcitonin on progression of structural disease as well as evalu-
ating inhibition of the inducible nitric oxide synthase pathway, believed
to be responsible for inﬂammatory and catabolic pathways in cartilage
leading to OA.
Conclusions: Inhibition of both peripheral and central pain pathways
has been shown to be effective at reducing pain and improving function
in people with OA. Further studies are needed to deﬁne the safety
proﬁle of therapy directed at inhibition of NGF. Disease modiﬁcation
remains a challenging goal, but a better understanding of the mecha-
nism of cartilage damage has allowed new agents to be considered for
study in this condition.
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NOVEL AND TARGETED THERAPIES FOR OA
N. Lane. Univ. of California at Davis, Ctr. for Musculoskeletal and Aging
Res., Sacramento, CA
The treatment of osteoarthritis (OA) and its associated pain remains an
unmet medical need, and our limited ability to effectively treat the
disease is due to deﬁcits in our understanding of both the pathophys-
iology of OA and the factors associated with the progression of the
disease. However, a number of novel and targeted treatments for
painful knee OA have been studied and demonstrate efﬁcacy, and
a selected number will be discussed.
Novel therapies. Recent studies of monoclonal antibodies that inhibit
nerve growth factor have been studied in moderate to severe knee
OA:tanezumab, injected every 8 weeks was found to reduce walking
knee pain nearly 50% more than placebo-treated subjects, and subjects
reported signiﬁcant improvement in pain and function over the 16
week study. A selective serotonin reuptake inhibitor approved for the
treatment of chronic painful conditions including ﬁbromyalgia
(duloxetine (60-120 mg/d)) was evaluated in an RCT of 250 subjects
with moderate knee OA for 13 weeks, and compared to a placebo
group it reduced knee pain by more than 50% and also improved
function. Exercise regimens have also had some success in the treat-
ment of pain from knee OA. Tai chi twice a week for 12 weeks was
evaluated in an RCT. WOMAC pain, WOMAC physical function and
physician VAS improved by 70% in the tai chi group from baseline, and
all outcome differences were p<0.05 compared to the attention-only
control group.
Targeted therapies. Since knee OA is frequently a localized disease, the
use of targeted local treatments has been studied. Intra-articular
injections of viscosupplementation have been used for the treatment of
knee pain. A comparator study of Hylan GF-20 (3 weekly injections) and
Sodium Hyaluronate (5 weekly injections) found signiﬁcant reduction
in knee pain by VAS, however it was sustained for 12 months in the
Hylan GF-20 group, and only for 6 months with Sodium Hyaluronate.
Interestingly, an RCTof Hylan GF-20 vs. placebowith treatments every 6
months for 24 months demonstrated a signiﬁcant beneﬁcial effect on
knee cartilage preservation measured by both cartilage volume and
cartilage defects. Onabotulinumtoxin A directly blocks peripheral
sensation through suppression of inﬂammatory neuropeptides arising
from sensory neurons, and can block both localized and central pain. An
RCT of onabotulinumtoxin A (100 U, 200 U) vs. methylprednisolone
40 mg found signiﬁcant reduction in VAS pain from baseline which was
sustained longer in the onabotulinumtoxin A group. Physical joint
distraction has been performed in a small study, and the reduction in
WOMAC pain subscale during the treatment was further improved and
maintained through 10 months post-distraction. Transplantation of
mesenchymal stem cells is also being evaluated but clinical studies
currently are lacking.I-9
PERIFIBRILLAR PROTEINS IN THE CARTILAGE EXTRACELLULAR
MATRIX
R. Wagener. Ctr. for Biochemistry, Univ. of Cologne, Cologne, Germany
To fulﬁl its function as a ﬂexible but simultaneously strongly supportive
tissue, a proper cartilage is dependent on the scaffold that is formed by
a network of large collagen ﬁbrils that are embedded in a proteoglycan
gel. However, to form, organise and maintain these macromolecular
networks accessory proteins are needed. A subset of such proteins is
found close to or at the surface of the collagen ﬁbrils, thereby creating
a “periﬁbrillar”matrix of a deﬁned composition. The periﬁbrillar matrix
may be of relevance for the regulation of collagen ﬁbrillogenesis and for
interactions between large collagen ﬁbrils, for their interactionwith the
proteoglycan gel and for interactions between large ﬁbrils and the
collagen VI containing microﬁbrils. Examples for pericellular proteins
are non-ﬁbril forming collagenmolecules of the FACIT type, small leucin
rich repeat proteoglycans as well as other abundant noncollagenous
proteins, like COMP (cartilage oligomeric matrix protein) and matrilins.
These all participate in the formation of ﬁbrillar or ﬁlamentous struc-
tures and mediate interactions between collagen ﬁbrils and other
matrix constituents. Interestingly, whereas the ablation of the Col2a1 or
the Acan genes in mice is perinatal lethal, the ablation of genes coding
for periﬁbrillar proteins leads to much milder phenotypes or shows
disturbances only detectable at the molecular level, perhaps indicating
redundancy due to the multiplicity of interconnections between these
proteins. In contrast, more severe phenotypes are observed when
mutations in genes coding for periﬁbrillar proteins affect protein
folding in the secretory pathway which leads to ER stress due to an
unfolded protein response. The lack of obvious phenotypes in single
knockouts of periﬁbrillar proteins can be partially overcome by the
generation of multiple knockouts, but even these mice often show only
mild phenotypes. Consequently, our current knowledge of the in vivo
function of pericellular proteins is predominantly based on in vitro
studies. We recently found that zebraﬁsh, a less complex vertebrate
animal model organism, is an alternative to study pericellular protein
function in vivo. When investigating the function of the prototypic
periﬁbrillar protein matrilin-1 in zebraﬁsh larvae we found that in
contrast to in mouse the knockdown of matrilin-1 by morpholino
antisense oligonucleotides has drastic consequences for cartilage
development and a proper cartilage is not formed. Instead, a mesen-
chymal tissue develops that lacks the major cartilage components
collagen II and aggrecan. Moreover, in severely affected larvae the cells
display “chondroptosis”, a variant of apoptosis in chondrocytes. Taken
together it is likely that the loss of matrilin-1 has an effect already
within the secretory pathway, where matrilin-1 may facilitate the
secretion of bulk extracellular matrix components. Nevertheless, it
remains obscure why this obvious phenotype occurs in zebraﬁsh and
not in mouse.
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OA BIOMARKERS: HOW WILL WE RECOGNIZE THE REAL MCCOY?
G. Moxley. Virginia Commonwealth Univ., Richmond, VA
This presentation aims to provide a conceptual overview for the OA
biomarkers session. A biomarker may be deﬁned thus: “a characteristic
[distinctive mark, trait, or feature] that is objectively measured and
evaluated as an indicator of normal biological processes, pathogenic
processes, or pharmacological responses to a therapeutic intervention.”
Implicit is that the biomarker lies along a pathogenetic pathway leading
to a clinical endpoint (how the patient feels, functions, or survives). A
surrogate marker may be thought of as a biomarker that approximates
a clinical endpoint and is expected to predict a clinical beneﬁt or harm.
One sees at once that current OA interventions are neither preventive
nor curative, and signiﬁcant obstacles block development. We can
expect that -omic and experimental biology investigations will outline
OA pathogenetic pathways, and so can anticipate ﬁnding biomarkers
among such pathways. Biomarkers could detect early OA, help under-
standing of pathogenesis, lead to prediction of outcome and alter
management, and aid drug development. In anticipation, a preliminary
classiﬁcation for OA biomarkers has been developed; its acronym BIPED
refers to Burden of disease, Investigative, Prognostic, Efﬁcacy of inter-
vention, and Diagnostic, with the later addition of Safety. To identify
useful biomarkers, we require clinical endpoints that deﬁne how an OA
patient feels and functions. The recent description of virtual joint
